Recent studies have highlighted the potential benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with CA, particularly in reducing the risk of heart failure hospitalizations and improving the clinical outcome [31]. This evidence concerns the gene SLC5A2 and heart failure.